Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with significant toxicity. Cytokine release syndrome (CRS) ...

Source: Journal of Hematology and Oncology - March 2, 2018 Category: Hematology Authors: David Porter, Noelle Frey, Patricia A. Wood, Yanqiu Weng and Stephan A. Grupp Tags: Review Source Type: research